COMMUNIQUÉS West-GlobeNewswire

Cellectis Reports Financial Results for First Quarter 2024
28/05/2024
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 2024 1 ; cash runway projection into 2026 2 • Conference call and webcast [...]
Information on the Total Number of Voting Rights and Shares
28/05/2024
REGULATED INFORMATION Information on the Total Number of Voting Rights and Shares Mont-Saint-Guibert (Belgium), May 28, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the [...]
Informations sur le Nombre Total de Droits de Vote et d'Actions
28/05/2024
INFORMATION RÉGLEMENTÉE Informations sur le Nombre Total de Droits de Vote et d'Actions Mont-Saint-Guibert (Belgique), le 28 mai 2024, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 [...]
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
28/05/2024
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck [...]
NANOBIOTIX annonce une présentation de nouvelles données et du programme d’immunothérapie de Phase 1 lors de la réunion annuelle 2024 de l’American Society for Clinical Oncology (ASCO) suivi d’une conférence téléphonique et webcast
28/05/2024
Nouvelles données de la partie escalade de dose terminée et de la partie expansion en cours de l’étude 1100, une étude de Phase 1 en cours aux Etats-Unis, évaluant NBTXR3 suivi d’un anti-PD-1 chez des patients atteints [...]
Compass Therapeutics Announces CEO Transition
28/05/2024
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human [...]
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
28/05/2024
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and [...]
Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
28/05/2024
SAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ [...]
Acasti Pharma to Attend BIO International Convention 2024
28/05/2024
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel, injectable formulation of nimodipine that [...]
Anika Enters into Cooperation Agreement with Caligan Partners
28/05/2024
Appoints Joseph Capper and William Jellison to Board of Directors Announces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc . (NASDAQ: ANIK), a global [...]
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
28/05/2024
Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful improvements in the signs and [...]
Standard BioTools Purchases the Carterra® LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers
28/05/2024
SOUTH SAN FRANCISCO, Calif and SALT LAKE CITY, May 28, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced that it has purchased the LSA XT system from Carterra ® , a leading provider of high- [...]
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
28/05/2024
LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Merus N.V. Announces Proposed Public Offering of Common Shares
28/05/2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length [...]
Cytokinetics Announces Closing of Public Offering of Common Stock
28/05/2024
SOUTH SAN FRANCISCO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 9,803,922 shares of its [...]
Sharps Technology Positioned to Address Supply Chain Disruptions Resulting from Recent FDA Recalls, Warnings, and Tariffs on Chinese Manufactured Syringes
28/05/2024
Sharps CEO issues letter to shareholders on FDA actions and tariffs affecting Chinese syringes. The FDA began raising quality concerns over Chinese-manufactured syringes in November 2023, resulting in multiple recalls [...]
Annual General Meeting of Ipsen S.A. held on 28 May 2024
28/05/2024
All the resolutions submitted to the shareholders’ vote have been adopted PARIS, FRANCE, 28 May 2024 - The Annual General Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY) was held today at the Salons de l'Hôtel des [...]
Assemblée Générale Annuelle d’Ipsen S.A. du 28 mai 2024
28/05/2024
Toutes les résolutions soumises au vote des actionnaires ont été adoptées PARIS, FRANCE, 28 mai 2024 - L’Assemblée Générale Annuelle de la société IPSEN S.A. (Euronext : IPN ; ADR : IPSEY) s’est réunie aujourd’hui aux [...]
Altamira Therapeutics Provides Business Update
28/05/2024
Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticles Pursuing partnering opportunities with AM-125 legacy asset in vertigo and / [...]

Pages